▁Introduction 7.8203125
: 1.9072265625
<0x0A> 6.51953125
In 3.416015625
▁a 3.43359375
▁significant 6.97265625
▁break 4.125
through 0.67919921875
▁for 1.7177734375
▁cancer 5.59765625
▁treatment 2.4921875
, 0.21044921875
▁British 6.40234375
▁bi 4.44921875
ote 0.3486328125
ch 0.452392578125
▁firm 0.6904296875
, 2.19140625
▁[ 8.9765625
Company 7.51171875
▁Name 1.39453125
], 0.94091796875
▁has 0.6513671875
▁recently 2.892578125
▁announced 0.67724609375
▁positive 4.92578125
▁results 0.3046875
▁from 0.1300048828125
▁their 3.46875
▁experimental 5.4375
▁cancer 1.55078125
▁drug 1.08984375
. 2.384765625
▁The 0.63330078125
▁drug 0.66943359375
▁has 2.330078125
▁shown 0.9892578125
▁prom 1.373046875
ising 0.00045013427734375
▁effic 3.083984375
acy 0.00081634521484375
▁in 0.150146484375
▁clin 3.369140625
ical 0.00063323974609375
▁tri 0.0236663818359375
als 8.177757263183594e-05
, 0.59375
▁bringing 6.984375
▁hope 0.2379150390625
▁to 0.125732421875
▁the 2.580078125
▁millions 0.64697265625
▁of 0.0887451171875
▁cancer 1.2041015625
▁patients 0.0191802978515625
▁world 0.344970703125
wide 0.0004322528839111328
. 0.203857421875
▁However 4.84375
, 0.0008187294006347656
▁anal 8.703125
yst 0.01922607421875
s 0.006412506103515625
▁are 1.3935546875
▁express 6.23046875
ing 0.0003345012664794922
▁ca 1.6953125
ution 0.00017261505126953125
▁and 2.814453125
▁emphas 3.4296875
izing 0.11895751953125
▁the 0.1746826171875
▁need 0.26220703125
▁for 0.037628173828125
▁further 0.54833984375
▁research 1.0234375
▁and 0.6015625
▁regul 2.712890625
atory 0.00020444393157958984
▁appro 0.026763916015625
val 3.600120544433594e-05
s 1.912109375
▁before 0.342529296875
▁considering 6.7578125
▁it 2.892578125
▁a 0.64501953125
▁definit 3.580078125
ive 0.0007185935974121094
▁cancer 3.185546875
▁treatment 0.849609375
. 0.18310546875
<0x0A> 0.366943359375
Prom 4.953125
ising 0.0185394287109375
▁C 2.201171875
lin 0.0028781890869140625
ical 0.0004742145538330078
▁Tri 0.0858154296875
als 0.89794921875
: 0.86962890625
<0x0A> 0.38525390625
[ 2.46484375
Company 0.0165252685546875
▁Name 0.006256103515625
] 0.096923828125
' 2.591796875
s 0.00036334991455078125
▁cancer 2.34375
▁drug 0.048126220703125
▁has 0.314453125
▁exhib 5.81640625
ited 0.0001436471939086914
▁early 8.0390625
- 3.6796875
stage 0.048675537109375
▁success 1.7353515625
▁in 0.1661376953125
▁clin 0.44482421875
ical 0.00018775463104248047
▁tri 0.01126861572265625
als 1.919269561767578e-05
, 0.413818359375
▁providing 3.958984375
▁renew 4.9453125
ed 9.191036224365234e-05
▁optim 1.4892578125
ism 8.213520050048828e-05
▁in 1.8193359375
▁the 0.08392333984375
▁fight 0.38525390625
▁against 0.00030493736267089844
▁cancer 0.1761474609375
. 0.005008697509765625
▁In 2.068359375
▁a 0.642578125
▁carefully 7.578125
▁controlled 0.95458984375
▁study 1.1689453125
▁involving 2.259765625
▁several 5.640625
▁cancer 2.119140625
▁patient 5.5078125
▁coh 2.26171875
ort 2.4199485778808594e-05
s 0.00121307373046875
, 0.033538818359375
▁the 0.111083984375
▁drug 0.094482421875
▁demonstrated 1.677734375
▁notable 4.328125
▁effect 4.12890625
iveness 0.00623321533203125
▁in 0.34765625
▁in 3.498046875
hib 0.0009326934814453125
iting 0.0004930496215820312
▁tum 0.44970703125
or 0.0799560546875
▁growth 0.07489013671875
▁and 0.442626953125
, 7.2578125
▁in 0.1402587890625
▁some 0.07513427734375
▁cases 0.0469970703125
, 0.00141143798828125
▁even 1.5166015625
▁indu 1.5
cing 0.0018901824951171875
▁tum 0.90380859375
or 0.004001617431640625
▁regression 0.473876953125
. 0.0265350341796875
▁These 2.134765625
▁encourag 2.80078125
ing 3.1113624572753906e-05
▁results 0.4140625
▁have 0.6181640625
▁spark 2.52734375
ed 1.8835067749023438e-05
▁excitement 1.4375
▁within 2.533203125
▁the 0.00858306884765625
▁medical 0.716796875
▁community 0.044464111328125
. 3.46875
<0x0A> 0.09942626953125
Me 6.50390625
chan 0.38134765625
ism 0.03411865234375
▁of 0.032012939453125
▁Action 0.0166778564453125
: 0.06085205078125
<0x0A> 0.1434326171875
The 0.4912109375
▁success 5.34765625
▁of 0.00627899169921875
▁[ 0.51123046875
Company 0.003047943115234375
▁Name 0.00481414794921875
] 0.015167236328125
' 0.021820068359375
s 0.0002510547637939453
▁cancer 0.2044677734375
▁drug 0.042205810546875
▁can 1.2880859375
▁be 0.03790283203125
▁attributed 0.041107177734375
▁to 0.0310211181640625
▁its 0.037567138671875
▁unique 0.45654296875
▁mechanism 0.081787109375
▁of 0.0014810562133789062
▁action 0.0006008148193359375
. 0.09564208984375
▁By 3.248046875
▁target 0.388671875
ing 0.00028896331787109375
▁specific 1.15625
▁gen 2.43359375
etic 1.03515625
▁mut 0.91845703125
ations 0.0012044906616210938
▁pre 5.55859375
val 0.00823974609375
ent 0.0001627206802368164
▁in 0.0157928466796875
▁various 2.615234375
▁cancer 0.89453125
▁types 0.2391357421875
, 0.003528594970703125
▁the 0.045989990234375
▁drug 0.007049560546875
▁effectively 1.830078125
▁dis 1.1650390625
rupt 0.037017822265625
s 7.43865966796875e-05
▁tum 2.12890625
or 0.00811004638671875
▁cell 1.3623046875
▁pro 1.6552734375
l 0.01276397705078125
ifer 4.172325134277344e-06
ation 0.00020229816436767578
▁and 0.57666015625
▁surv 1.99609375
ival 0.0014925003051757812
, 0.759765625
▁offering 5.1640625
▁a 0.408447265625
▁potential 2.287109375
▁break 3.505859375
through 0.000553131103515625
▁in 0.1905517578125
▁personal 3.66015625
ized 0.0010356903076171875
▁medicine 2.123046875
. 0.1148681640625
▁Its 5.703125
▁ability 1.892578125
▁to 0.00012683868408203125
▁combat 5.25
▁cancer 1.744140625
▁cells 2.662109375
▁while 1.015625
▁minim 1.76171875
izing 0.016326904296875
▁damage 1.7109375
▁to 0.0012941360473632812
▁health 0.06597900390625
y 0.00013303756713867188
▁cells 0.54052734375
▁sets 3.701171875
▁it 0.0162353515625
▁apart 0.0003483295440673828
▁from 0.00377655029296875
▁conventional 2.380859375
▁treatment 3.890625
▁approaches 2.376953125
▁like 5.19921875
▁chem 0.04083251953125
other 0.0028896331787109375
apy 8.83340835571289e-05
▁and 0.67333984375
▁radiation 0.4501953125
▁ther 0.33837890625
apy 0.00048089027404785156
. 0.40673828125
<0x0A> 0.0192108154296875
Enc 7.765625
ou 0.00951385498046875
rag 0.0027828216552734375
ing 0.047698974609375
▁Pat 3.26171875
ient 0.012298583984375
▁Res 3.66796875
p 0.0011186599731445312
ons 4.4226646423339844e-05
es 0.0002779960632324219
: 0.0146942138671875
<0x0A> 0.0025177001953125
The 1.5498046875
▁drug 2.73046875
' 0.36669921875
s 6.687641143798828e-05
▁success 2.3203125
▁stories 6.78125
▁are 0.92529296875
▁not 1.6455078125
▁limited 0.34619140625
▁to 0.008453369140625
▁labor 1.8388671875
atory 0.0276031494140625
▁results 2.48828125
▁alone 1.619140625
. 0.1361083984375
▁Test 6.79296875
imon 0.029205322265625
ies 1.5751953125
▁from 0.0916748046875
▁patients 1.0908203125
▁involved 4.203125
▁in 0.0014781951904296875
▁the 0.5869140625
▁clin 0.225341796875
ical 0.00012969970703125
▁tri 0.09259033203125
als 1.895427703857422e-05
▁further 4.1640625
▁support 3.650390625
▁the 0.744140625
▁drug 0.311279296875
' 0.0029449462890625
s 1.3589859008789062e-05
▁effic 0.67724609375
acy 2.872943878173828e-05
. 0.455810546875
▁Many 1.73828125
▁patients 1.1318359375
▁reported 1.453125
▁improvements 4.08203125
▁in 0.01091766357421875
▁their 0.26171875
▁overall 1.50390625
▁health 0.426513671875
▁and 0.58447265625
▁quality 1.33984375
▁of 0.0003452301025390625
▁life 0.00014865398406982422
, 0.251953125
▁with 0.9580078125
▁some 0.56884765625
▁even 0.6943359375
▁experien 0.6162109375
cing 3.814697265625e-06
▁long 3.55859375
- 0.0020618438720703125
last 2.294921875
ing 5.6624412536621094e-05
▁rem 0.2164306640625
ission 0.21630859375
. 0.876953125
▁These 1.38671875
▁remarkable 2.99609375
▁responses 2.09375
▁are 2.21875
▁a 0.94775390625
▁be 5.6015625
acon 0.0032062530517578125
▁of 0.0005731582641601562
▁hope 0.006038665771484375
▁for 0.08160400390625
▁patients 2.908203125
▁who 1.9462890625
▁have 0.1578369140625
▁exha 1.0283203125
usted 4.0531158447265625e-06
▁other 2.935546875
▁treatment 0.148193359375
▁options 0.00681304931640625
. 0.35888671875
<0x0A> 0.00786590576171875
Anal 3.251953125
yst 0.07989501953125
s 0.1751708984375
▁Ur 3.208984375
ge 0.05828857421875
▁Ca 0.12005615234375
ution 5.3882598876953125e-05
▁and 4.765625
▁Further 1.5029296875
▁Research 0.0943603515625
: 0.015411376953125
<0x0A> 0.0029354095458984375
Des 0.76806640625
p 4.887580871582031e-06
ite 3.5762786865234375e-07
▁the 0.211181640625
▁positive 1.986328125
▁out 1.9130859375
comes 0.17724609375
, 0.55615234375
▁anal 0.382568359375
yst 0.00013244152069091797
s 0.00039458274841308594
▁and 2.359375
▁industry 2.796875
▁exper 0.1043701171875
ts 2.7418136596679688e-06
▁are 0.9140625
▁ur 1.0478515625
ging 0.0001310110092163086
▁ca 0.02301025390625
ution 9.298324584960938e-06
▁and 0.513671875
▁advoc 4.0703125
ating 0.0237579345703125
▁for 0.0792236328125
▁further 0.267333984375
▁research 0.09832763671875
▁into 4.171875
▁the 0.0946044921875
▁drug 0.0880126953125
' 0.1072998046875
s 1.895427703857422e-05
▁long 1.068359375
- 0.0003814697265625
term 0.00014591217041015625
▁effects 1.396484375
▁and 0.86279296875
▁safety 1.3388671875
▁profile 0.5595703125
. 0.01311492919921875
▁Rec 6.4375
ogn 2.392578125
izing 0.0081939697265625
▁that 1.62109375
▁clin 2.892578125
ical 0.0004680156707763672
▁tri 0.048187255859375
als 3.0994415283203125e-06
▁are 0.7431640625
▁often 2.4609375
▁conducted 3.494140625
▁on 1.0810546875
▁a 0.806640625
▁relatively 2.521484375
▁small 0.033966064453125
▁sample 1.5712890625
▁size 0.03546142578125
, 0.310302734375
▁they 0.8564453125
▁emphas 0.7607421875
ize 0.0014867782592773438
▁the 0.07415771484375
▁need 0.2509765625
▁for 0.0298004150390625
▁larger 1.1630859375
, 1.3671875
▁more 0.46484375
▁rig 2.849609375
orous 0.03875732421875
▁studies 0.478271484375
▁to 0.505859375
▁determine 2.716796875
▁the 0.08734130859375
▁drug 0.04205322265625
' 0.0010585784912109375
s 1.2993812561035156e-05
▁true 1.2412109375
▁potential 1.404296875
▁and 2.19140625
▁any 2.03125
▁potential 0.304443359375
▁ad 1.638671875
verse 7.152557373046875e-07
▁effects 0.3662109375
. 0.09747314453125
▁Additionally 3.068359375
, 0.00015556812286376953
▁regul 0.71728515625
atory 0.02056884765625
▁appro 0.11279296875
val 1.621246337890625e-05
▁from 3.44140625
▁the 1.265625
▁relevant 2.8984375
▁authorities 0.583984375
▁is 0.63525390625
▁imper 4.51171875
ative 2.1576881408691406e-05
▁to 1.1669921875
▁ensure 0.10980224609375
▁patient 2.392578125
▁safety 0.0081329345703125
▁and 0.339599609375
▁the 2.86328125
▁drug 0.335205078125
' 0.0020904541015625
s 4.458427429199219e-05
▁commercial 4.26171875
▁vi 1.0576171875
ability 2.6226043701171875e-05
. 0.0301666259765625
<0x0A> 0.0237274169921875
P 3.859375
ot 0.0953369140625
ential 0.005832672119140625
▁Ch 3.001953125
alleng 0.0011301040649414062
es 0.00014865398406982422
▁and 0.58447265625
▁Lim 2.203125
itations 0.00156402587890625
: 0.016815185546875
<0x0A> 0.0006279945373535156
A 4.6328125
part 1.2158203125
▁from 1.633167266845703e-05
▁the 0.62109375
▁concerns 3.951171875
▁over 2.537109375
▁safety 1.5712890625
▁and 0.06414794921875
▁long 2.6796875
- 0.00031757354736328125
term 0.00028705596923828125
▁effic 0.425048828125
acy 2.384185791015625e-06
, 0.00844573974609375
▁several 2.912109375
▁challeng 1.8046875
es 0.0005831718444824219
▁and 0.79638671875
▁limitations 0.01094818115234375
▁need 4.01171875
▁to 0.0302581787109375
▁be 0.00036144256591796875
▁taken 4.76953125
▁into 0.002025604248046875
▁account 0.54296875
. 0.5458984375
▁The 1.345703125
▁drug 0.5107421875
' 0.188232421875
s 1.52587890625e-05
▁cost 1.927734375
▁and 1.9501953125
▁access 1.080078125
ibility 0.002719879150390625
▁may 1.541015625
▁pose 2.4140625
▁bar 2.9375
riers 0.00015032291412353516
▁to 0.375
▁w 1.60546875
ides 2.5033950805664062e-06
p 8.928775787353516e-05
read 2.2411346435546875e-05
▁use 1.8505859375
. 2.7109375
▁Additionally 1.02734375
, 3.421306610107422e-05
▁potential 4.38671875
▁drug 1.666015625
▁resistance 0.7529296875
▁and 0.9267578125
▁vari 6.59375
ability 0.003143310546875
▁in 0.098388671875
▁patient 0.63916015625
▁response 1.533203125
▁highlight 4.625
▁the 0.04376220703125
▁need 0.208984375
▁for 0.0168304443359375
▁deeper 8.6328125
▁investig 4.6796875
ations 0.0040740966796875
▁and 2.046875
▁tail 3.787109375
ored 0.026123046875
▁treatment 0.258056640625
▁strateg 1.4638671875
ies 1.6689300537109375e-06
. 0.08624267578125
<0x0A> 0.448974609375
Look 3.771484375
ing 0.005435943603515625
▁A 1.0390625
head 4.208087921142578e-05
: 0.08734130859375
<0x0A> 4.984375
[ 3.380859375
Company 0.0026760101318359375
▁Name 0.0017156600952148438
] 0.026092529296875
' 0.253173828125
s 0.00015413761138916016
▁cancer 0.5615234375
▁drug 0.0202484130859375
▁shows 4.4453125
▁immense 2.3203125
▁promise 0.2115478515625
▁in 0.67236328125
▁the 0.365966796875
▁treatment 3.83203125
▁of 0.0123138427734375
▁various 0.697265625
▁cancer 0.26611328125
▁types 0.00925445556640625
, 1.33984375
▁providing 2.74609375
▁a 0.927734375
▁g 1.833984375
lim 0.050872802734375
mer 7.62939453125e-06
▁of 0.00011432170867919922
▁hope 0.006011962890625
▁for 0.52197265625
▁patients 1.3359375
▁and 1.4453125
▁health 4.2109375
care 0.0203704833984375
▁profession 0.6005859375
als 2.6226043701171875e-06
. 1.5537109375
▁While 1.33984375
▁c 6.0703125
aut 0.00045180320739746094
ious 0.02410888671875
▁optim 0.048797607421875
ism 7.021427154541016e-05
▁has 6.4765625
▁g 7.0234375
ri 0.003253936767578125
pped 1.5735626220703125e-05
▁the 0.013946533203125
▁field 4.43359375
, 0.10198974609375
▁it 1.65234375
▁is 0.25634765625
▁essential 1.4072265625
▁to 0.0303192138671875
▁conduct 4.171875
▁further 1.033203125
▁studies 1.8984375
▁and 0.339599609375
▁obtain 1.4658203125
▁regul 0.0986328125
atory 2.5153160095214844e-05
▁appro 0.004650115966796875
val 4.1484832763671875e-05
▁to 2.998046875
▁fully 3.015625
▁compreh 4.0859375
end 0.00022935867309570312
▁the 0.1278076171875
▁drug 0.0248260498046875
' 0.0022830963134765625
s 5.257129669189453e-05
▁potential 0.79296875
▁benefits 3.498046875
▁and 0.052520751953125
▁ris 1.9140625
ks 1.3113021850585938e-06
. 0.019775390625
▁The 2.2578125
▁collaboration 8.1484375
▁between 0.31884765625
▁the 2.548828125
▁bi 1.373046875
ote 0.0248870849609375
ch 0.048675537109375
▁company 1.626953125
, 1.36328125
▁medical 1.4833984375
▁community 3.111328125
, 0.01029205322265625
▁and 0.051055908203125
▁regul 0.172119140625
atory 0.055023193359375
▁bodies 0.96044921875
▁will 1.6181640625
▁be 1.0556640625
▁cru 0.6259765625
cial 4.887580871582031e-06
▁in 0.2315673828125
▁adv 1.9658203125
ancing 5.3882598876953125e-05
▁this 2.49609375
▁ground 2.78125
- 2.294921875
bre 0.00011563301086425781
aking 5.9604644775390625e-06
▁ther 2.51953125
apy 7.37905502319336e-05
▁towards 1.96875
▁becoming 3.36328125
▁an 3.59375
▁integral 1.990234375
▁part 0.256591796875
▁of 0.002429962158203125
▁cancer 0.31982421875
▁treatment 0.2259521484375
. 0.218994140625
<0x0A> 0.50439453125
Con 3.5703125
clusion 0.1710205078125
: 0.037811279296875
<0x0A> 8.734375
The 1.8076171875
▁positive 3.201171875
▁results 0.3115234375
▁show 7.82421875
c 0.56005859375
ased 0.049346923828125
▁by 0.08428955078125
▁[ 0.0572509765625
Company 0.0019512176513671875
▁Name 0.0028533935546875
] 0.0072479248046875
' 0.031097412109375
s 0.00031685829162597656
▁experimental 2.43359375
▁cancer 0.033721923828125
▁drug 0.034210205078125
▁have 2.3203125
▁brought 2.599609375
▁renew 0.990234375
ed 9.310245513916016e-05
▁hope 0.482177734375
▁to 0.333251953125
▁the 0.496337890625
▁cancer 2.947265625
▁community 1.1728515625
. 0.301025390625
▁While 0.873046875
▁anal 2.27734375
yst 0.000370025634765625
s 0.00038504600524902344
▁ur 1.2177734375
ge 0.002483367919921875
▁ca 0.045013427734375
ution 3.790855407714844e-05
▁and 0.1451416015625
▁call 2.953125
▁for 0.0004658699035644531
▁further 0.134765625
▁research 0.10003662109375
, 0.6943359375
▁the 0.330810546875
▁drug 0.62841796875
' 0.07415771484375
s 3.5643577575683594e-05
▁effic 3.8203125
acy 4.9591064453125e-05
▁in 1.1689453125
▁in 2.970703125
hib 0.00012195110321044922
iting 0.0002682209014892578
▁tum 0.007843017578125
or 0.005290985107421875
▁growth 0.013946533203125
▁and 0.1282958984375
▁impro 2.736328125
ving 1.5139579772949219e-05
▁patient 0.0870361328125
▁out 0.94677734375
comes 0.00039958953857421875
▁cannot 4.125
▁be 0.005615234375
▁over 0.927734375
look 0.81591796875
ed 6.282329559326172e-05
. 0.004016876220703125
▁As 0.90771484375
▁the 0.732421875
▁drug 1.7626953125
▁progress 1.9560546875
es 0.0007925033569335938
▁through 0.1302490234375
▁more 5.421875
▁compreh 2.748046875
ensive 1.9311904907226562e-05
▁tri 1.55859375
als 7.867813110351562e-06
▁and 0.3671875
▁regul 0.68994140625
atory 0.00015926361083984375
▁appro 0.0703125
val 3.8743019104003906e-05
s 0.47509765625
, 0.00867462158203125
▁its 1.6240234375
▁potential 0.26025390625
▁impact 3.263671875
▁on 0.035888671875
▁cancer 0.356201171875
▁treatment 0.1287841796875
▁could 3.5625
▁revolution 2.875
ize 0.0008625984191894531
▁the 0.260009765625
▁field 0.5224609375
▁and 1.5673828125
▁offer 2.064453125
▁renew 5.78515625
ed 0.0002124309539794922
▁prospect 6.078125
s 0.0012903213500976562
▁for 0.1522216796875
▁patients 0.96923828125
▁batt 4.609375
ling 0.000156402587890625
▁this 0.5419921875
▁dev 0.77880859375
ast 1.1920928955078125e-05
ating 0.0003058910369873047
▁disease 0.0550537109375
. 0.00930023193359375
